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Dear Editor,
We wish to provide some perspectives with re-
gard to an article recently published in your 
journal on polymorpisms of Gluthathion 
S-transferase in glaucoma patients [1]. 
Glutathione S-transferases (GSTs) are a group of 
genes, the polymorphisms of which have been 
reported to be also associated with an increased 
risk for Diabetes Mellitus (DM) [2], malignant 
diseases [3], and diabetic retinopathy [4].
Glutathione S-transferases (GSTs) represent 
a family of multifunctional phase II isoenzymes 
known for their capacity of catalyzing the con-
jugation of reduced glutathione with a large 
variety of electrophilic compounds, including 
carcinogenic agents and products derived from 
oxidative stress; it has a major role in neutraliz-
ing reactive oxygen species (ROS), and it is part 
of the cellular protection and detoxifying mech-
anisms, hence the important antioxidant role [3]. 
Three of these polymorphisms, namely GSTM1, 
GSTT1, and GSTP1 have raised special inter-
est, and therefore have been more intensive-
ly studied. GST enzymes are coded by at least 
eight distinct loci: alpha (GSTA), mu (GSTM), 
kappa (GSTK), omega (GSTO), pi (GSTP), sig-
ma (GSTS), theta (GSTT), and zeta (GSTZ). 
GSTM1 gene locus is found on the short arm of 
the first chromosome (1p13.3), and its homozy-
gous deletion causes complete lack of enzymat-
ic activity leading to an inability of producing 
GSTM1 protein (GSTM1 null). GSTT1 gene is 
located on chromosome 22q11.2. Deletion of the 
GSTT1 gene leads to a nonfunctional allele and 
the persons with homozygous deletion do not 
present functional enzymatic activity (GSTT1 
null). The GSTP1 gene is located on chromo-
some 11q13. A valine to isoleucine substitution 
affecting exon 5, codon 105 in the GSTP1 gene 
leads to a decreased enzymatic activity and a 
reduction of the capacity of the GST to conju-
gate reactive electrophilic compounds with glu-
tathione, thereby increasing the risk of lesions 
induced by free radicals [5]. 
Diabetic nephropathy (DN) is a common 
microvascular complication of DM being, along 
with arterial hypertension, one of the causes that 
lead to end-stage renal disease and also a major 
cause of premature morbidity and mortality in 
diabetic patients. This complication is manifest-
ed through an increase in the urinary albumin 
secretion (albuminuria) which gradually pro-
gresses to overt albuminuria and finally leads to 
renal failure, without the presence of other caus-
es of renal disease. Usually, DN associates other 
micro- or macrovascular complications [6]. The 
risk for albuminuria is more importantly corre-
lated with the degree of the glycemic imbalance 
and the evolution of DM time, but a familial 
susceptibility also exists, which supports the 
role of genetic factors in the ethiopathogeny of 
DN. Probably, there is a high number of allelic 
variants that interact, and together with environ-
mental factors and a metabolic imbalance they 
could generate an individual susceptibility re-
garding the relative risk of DN occurrence [7]. 
Oxidative stress is recognized as a causative 
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agent in the ethiopathogeny of DN. The ROS 
level increases in parallel with the degree of ox-
idative stress and it is responsible for oxidative 
lesions affecting DNA and proteins having a 
major role in the pathogenesis of many diseases 
(tumors, coronary artery disease, diabetes mel-
litus). Renal involvement is preceded by an im-
balance between the oxidative and antioxidant 
activity and it has been found that the degree of 
oxidant lesions increases simultaneously with 
the progression of the disease. The severity of 
albuminuria is used as a marker for DN and an 
indicator for systemic lesions of the endothelial 
cells, although advanced modifications of the re-
nal structures are already present when it occurs 
[8]. Due to the fact that GSTM1 null, GSTT1 
null, and GSTP1 Val alleles are associated with 
a reduction of enzymatic activity, a hypothesis 
can be stated according to which inadequate 
GST enzymes levels in the presence of increased 
oxidative stress can predispose to microvascular 
complications such as DN in DM. Our previous 
studies have suggested that the Val allele of the 
GSTP1 Ile105Val gene polymorphism corre-
lates with the susceptibility for T2DM but not 
with the risk for peripheral diabetic neuropathy 
[2]. Data reported to date regarding correla-
tions between the GSTM1, GSTT1, and GSTP1 
Ile105Val gene polymorphisms and albuminuria 
in patients with diabetes mellitus are relatively 
rare and inconsistent. Doney et al. proved that 
the GSTT1 null genotype correlates with a gen-
eralized vasculopathy with a subsequently in-
creased risk for DN and retinopathy in patients 
with T2DM [9]. Hovnik et al. have completed a 
study in which they included patients with type 
1 Diabetes Mellitus (T1DM) and they observed 
that the presence of GSTM1 gene polymorphism 
was seen more frequently in patients with dia-
betic retinopathy but not in case of DN. Also, 
no statistically significant differences have been 
shown regarding the frequency of GSTT1 geno-
type polymorphism in patients with T1DM with 
or without diabetic retinopathy or nephropathy. 
GSTM1 null and GSTT1 null genotype combi-
nations which are followed by a complete lack of 
enzymatic activity have not been associated with 
an increased risk of either diabetic retinopathy 
or nephropathy [10]. A pertinent meta-analysis 
regarding the effect of GSTs (GSTM1, GSTT1, 
and GSTP1) gene polymorphisms on the risk 
of DN that analyzed 9 publications and includ-
ed 874 patients with T1DM and T2DM in the 
study group and 966 in the control group was 
published in 2015 by J. Orlewski et al. [7]. This 
meta-analysis showed that the GSTM1 null gen-
otype was statistically correlated with the risk of 
DN in Asians, but not in Caucasians; also, when 
only T2DM patients were analyzed no statisti-
cally significant correlation was found between 
the GSTM1 null genotype and DN. The GSTT1 
null genotype was not associated with DN even 
after stratified analysis was performed based on 
ethnicity, T2DM presence, sample size or pres-
ence of diabetic retinopathy. No correlation be-
tween the GSTP1 genotype and DN was found 
in the overall or subgroups analysis published 
by J. Orlewski et al. [7]. However, authors men-
tioned that the data obtained must be carefully 
interpreted due to a large number of confounding 
factors, the relatively small number of patients 
included in each study, the ethnic heterogenei-
ty and they consider that further investigations 
are required for exploring the correlation of the 
above-mentioned polymorphisms with the risk 
of DN. Contradictory and inconsistent data ob-
tained from genetic studies leave room for further 
investigations with the purpose of establishing 
the role of the polymorphisms of GST genes in 
the development of microvascular complications 
in diabetes mellitus, including DN. Discovery of 
novel genetic markers that can be correlated with 
the risk for these complications in the context of 
an increasing worldwide DM prevalence could 
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help in developing personalized prevention and 
therapeutic strategies.
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